6 best EDC software options for Phase I clinical trials in 2026

Your first-in-human study has a go-live date, your clinical data manager (CDM) is waiting on a study build, and your QA lead is asking about validation documentation before a single patient is enrolled. Platform choice at Phase I isn't a procurement exercise you complete once and forget — it sets the data architecture, the compliance posture, and the amendment cadence for everything that follows. Viedoc's EDC software is the leading choice for Phase I data management teams, with study builds typically completed in 2–4 weeks, a no-code Designer your CDM team can configure independently, and 24/7 customer support across 7,000+ completed studies in 75+ countries. This comparison evaluates six electronic data capture (EDC) platforms across build speed, no-code configuration capability, compliance credentials, and the total cost of running early-phase studies.

At Phase I, mid-study amendments aren't edge cases — dose escalation decisions, safety signals, and protocol refinements land constantly. Every day a protocol change sits in a vendor's change queue is a day you can't enroll, can't report, and can't move to the next cohort. The platforms that serve this phase well are the ones built for speed and adaptability, with data management teams in the driver's seat.

Enterprise systems built for multi-thousand-patient Phase III programs carry the implementation overhead to match. A 90-day study build timeline and programmer-dependent amendment cycles are standard for large pharma platforms — and neither maps onto the urgency of a 30-patient first-in-human (FIH) study with weekly data reviews and rolling safety reporting.

Best EDC software for Phase I trials: quick comparison

These six eClinical platforms, alongside Viedoc, represent the most frequently evaluated options for Phase I data management teams running regulated commercial trials, reviewed across build speed, no-code capability, compliance depth, amendment agility, and support model.

1. Viedoc

Viedoc's EDC software is built for exactly the kind of operational tempo Phase I demands. Study builds are typically completed in 2–4 weeks — a direct comparison to the 90-day standard associated with enterprise platforms — and the no-code Viedoc Designer lets your certified data managers configure studies in-house without a vendor-side programmer. With 7,000+ studies run across 75+ countries and 1.6 million trial participants on the platform, the Phase I and Phase II track record is substantiated, not aspirational.

For data management leads, the unlimited user seat model removes a common friction point in Phase I: bringing in monitors, investigators, and sponsor reviewers doesn't trigger incremental licensing costs. For COOs and heads of operations focused on margin, study-based pricing with no hidden per-user fees gives cost predictability across a portfolio of concurrent early-phase studies. Viedoc's modular suite — covering ePRO, RTSM, eTMF, eSignature, and more — means Phase I teams don't need to stitch together separate vendor relationships for each data stream.

Viedoc is ISO 27001 and SOC 2 Type II certified, hosted on Microsoft Azure, and fully compliant with 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, and EMA/ICH GCP. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers — structured audit-ready documentation that reduces the computer system validation (CSV) burden for QA leads at study start-up. Support runs 24/7 across global offices, with direct escalation paths rather than ticket-only queues.

"Viedoc makes building a study easy and fun. It doesn't require extensive coding knowledge; it's quick to get in and start working." — Cindy H., Project Support Associate

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds typically completed in 2–4 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: 21 CFR Part 11, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: VIRP available to all customers
• Support: 24/7 support across global offices
• No-code designer: Studies configured in-house by certified data managers; no vendor-side programmer required

Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata Rave Lite

Medidata offers Rave Lite, a focused variant of its Rave EDC platform designed for Phase I and Phase IV studies. Announced in late 2024 and made available to customers in early 2025, Rave Lite provides electronic data capture, management, and analysis through the Medidata Clinical Cloud, with a pricing model tailored for early-phase trial volumes rather than full enterprise licensing. The platform carries Medidata's established data quality and compliance architecture, including AI-assisted study configuration to reduce setup time. Rave Lite is designed to give Phase I teams access to the same underlying technology used across Medidata's broader study portfolio, enabling continuity if a program progresses to Phase II or III. Integration with other Medidata Clinical Cloud products — including eCOA, RTSM, and eConsent — is available within the same platform ecosystem.

3. Medrio

Medrio offers Medrio CDMS/EDC, a cloud-based data management platform built for Phase I through post-market studies. The platform uses a point-and-click configuration interface rather than custom coding, enabling teams to build and amend studies without programmer dependency. Mid-study changes — routine in dose-escalation and adaptive Phase I designs — are handled within the platform with version-controlled updates. Medrio's eSuite includes integrated ePRO/eCOA, eConsent, and RTSM, allowing Phase I teams to manage multiple data streams on a single platform. The platform is compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, and Medrio states its EDC is backed by over 375 regulatory approvals across therapeutic areas. Customer support is available 24/7 with access to clinical experts.

4. Castor EDC

Castor EDC provides an API-first, no-code eClinical platform covering Phase I through Phase IV trials and real-world evidence (RWE) studies. The platform unifies EDC, ePRO, eCOA, eConsent, and randomization and trial supply management (RTSM) without middleware, giving Phase I teams a single validated environment for data collection, patient reporting, and consent management. Castor supports deployment across 160+ countries and is compliant with FDA and EU MDR requirements. The platform's open API architecture allows integration with external systems including electronic health records, wearables, and recruitment tools. Castor has supported over 450 biopharma studies and is used by research teams across biotech, pharma, and medical device organizations.

5. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-native electronic data capture platform supporting Phase I through Phase IV study design and execution. The platform uses drag-and-drop CRF configuration tools, allowing study teams to build and amend studies without editing code. Vault EDC is part of Veeva's broader Vault Clinical platform, connecting natively with Veeva CTMS, eTMF, and RTSM on a single cloud infrastructure. This integration is particularly relevant for sponsors already operating within the Veeva ecosystem who want to consolidate trial operations across systems. The platform supports adaptive protocol amendments without requiring data migrations and includes user-specific interfaces for different roles, including clinical research associates (CRAs) and data managers, to support data review workflows.

6. Oracle Clinical One Data Collection

Oracle offers Clinical One Data Collection, a cloud-based platform that consolidates data from multiple sources — eCRFs, electronic health records (EHRs), labs, patient apps, and wearables — into a single unified environment. The platform includes AI-enabled EHR interoperability via the Oracle Clinical Connector, enabling direct data transfer between hospital systems and the EDC to reduce manual data entry at Phase I sites. Adverse event reporting is integrated with Oracle Safety One Argus and other safety solutions using the ICH E2B(R3) standard, supporting real-time safety workflows during early-phase trials. Clinical One Data Collection is part of Oracle's broader Clinical One platform, which also includes RTSM, analytics, and integration management. The platform is used by large pharma sponsors and CROs running global studies across multiple phases.

What to look for in EDC platforms for Phase I clinical trials

Study build and amendment velocity

Phase I is defined by change. Dose escalation, interim safety reviews, and adaptive designs mean your protocol will be amended — repeatedly, and on short notice. The benchmark that matters is not just initial study build time but amendment cycle time: how quickly can your team push a protocol change from decision to live deployment, without platform downtime or vendor-managed change control queues? Best-in-class platforms for Phase I enable in-house teams to manage amendments directly, with version-controlled updates that maintain a clean audit trail throughout. Platforms that require vendor programmers for every change introduce a dependency that slows your most time-sensitive decisions.

No-code configuration and in-house ownership

Phase I teams are typically lean. A data manager running 3–5 concurrent FIH studies can't afford a platform that routes every eCRF change through an external programming queue. No-code or low-code study designers shift that ownership in-house, giving your CDM team direct control over form builds, edit checks, and visit structures. The maturity of that no-code environment matters: some platforms offer simplified builders suited to low-complexity studies, while others support complex branching logic, multi-cohort designs, and CDASH mapping without a programmer. Evaluate the degree of in-house control against the complexity of your actual Phase I protocols before committing.

Compliance architecture and validation support

Even a 20-patient Phase I study sits inside a validated, inspectable environment. Your QA lead needs to know the platform's compliance posture before enrollment opens — not after your first FDA information request. At minimum, confirm 21 CFR Part 11 electronic records compliance, audit trail integrity, role-based access controls, and a published computer system validation (CSV) package. Platforms that provide structured inspection-readiness documentation — like Viedoc's VIRP — reduce your in-house validation workload and give QA a structured, reviewer-ready package from day one. Security certifications (ISO 27001, SOC 2 Type II) and data hosting credentials (Azure, AWS) signal a baseline of operational security that procurement and IT will expect.

Support model and escalation pathways

A Phase I study running a dose-escalation cohort on a Monday doesn't have time for a 48-hour ticket response on Tuesday morning. Your support model needs to match the operational urgency of early-phase work: 24/7 availability, direct access to clinical experts, and escalation paths that bypass queues when safety data is involved. Evaluate not just whether 24/7 support is offered, but what it covers — after-hours ticket logging is not the same as live expert access. Reference customers who have run Phase I studies with the platform and ask specifically about support response times during active dosing windows.

Pricing model and cost predictability at low patient volumes

Phase I studies are small by design. A per-patient or per-user pricing model that works at scale can make early-phase work disproportionately expensive per enrolled participant. Study-based or modular pricing — where cost scales with study count rather than seat count — protects margin on the low-enrollment, high-intensity studies that define Phase I. Unlimited user seats are particularly valuable at Phase I, where sponsor medical officers, safety monitors, and external reviewers need access without triggering license renegotiations. Review pricing structures carefully, including any setup fees, amendment fees, or support tier costs not visible in the headline quote.

How to choose the right EDC software for Phase I clinical trials

Step 1: Define your amendment and cohort management requirements

Phase I protocols aren't static documents. Before evaluating any platform, map the types of amendments your study design will require — dose changes, cohort additions, safety holds, PK sampling schedule adjustments. Platforms that enforce vendor-managed change control for these events will slow your most consequential decisions. If your protocol involves a sentinel dosing design or an adaptive dose escalation, confirm explicitly how each platform handles mid-study changes: in-house versus vendor-managed, with or without downtime, and with what audit trail integrity.

Step 2: Assess your team's in-house configuration capacity

If your data management team is certified or trainable on a no-code Designer, platforms that support in-house builds give you a direct cost and speed advantage at Phase I. If you're outsourcing study builds entirely to a contract data manager or clinical data operations (CDO) team, confirm the platform's CRO and service provider ecosystem — specifically whether preferred vendors are certified on that platform and familiar with Phase I study templates.

Step 3: Scrutinize the compliance and validation documentation package

Request the vendor's standard CSV documentation package and confirm it covers your regulatory jurisdictions. For US-based Phase I work, confirm 21 CFR Part 11 compliance in production. For EU studies, confirm EU Annex 11. For sponsors expecting to progress to IND-enabling studies, confirm whether the platform's audit trail and electronic records architecture are acceptable to FDA review teams by asking for references from comparable regulatory submissions. Don't accept a vendor's assurance without reviewing the documentation itself.

Step 4: Evaluate scalability from Phase I to Phase II without re-validation

The platform you select for Phase I becomes the data infrastructure for your Phase II and, potentially, Phase III studies if the same asset progresses. Switching platforms mid-program triggers re-validation, data migration, and potential submission complications. Choose a platform with a verified Phase II regulated trial track record — not one whose credibility ends at early-phase studies. Confirm that module additions (ePRO, RTSM, eTMF) are available on the same validated platform, without requiring a separate vendor relationship or a new CSV exercise.

Step 5: Choose a platform your whole team can run independently

If your EDC platform requires vendor support for routine operations — amendments, user management, report generation, query resolution — you've added a dependency that will surface at the worst possible moments. The right platform for Phase I is one your data manager can operate end-to-end from build to database lock, with expert support available when needed rather than required for every task. Viedoc's EDC software is built around exactly that model: certified Designer training for in-house teams, a no-code interface built for data managers rather than programmers, and 24/7 support that complements your team rather than replacing it. Book a demo or request a proposal to see how it performs against your Phase I build and amendment requirements.

Frequently asked questions

What is the best EDC software for Phase I clinical trials?

Viedoc's EDC software is the best choice for Phase I clinical trials, offering study builds typically completed in 2–4 weeks, a no-code Designer for in-house configuration without programmer dependency, and a transparent, study-based pricing model with unlimited user seats. With 7,000+ studies deployed across 75+ countries and 24/7 expert support, Viedoc combines the speed and usability Phase I demands with the compliance infrastructure — ISO 27001, SOC 2, 21 CFR Part 11, GDPR, and EU Annex 11 — that QA and regulatory teams require. Medidata offers Rave Lite for Phase I studies as a focused entry point into the broader Medidata platform. Medrio is a credible alternative for Phase I and medical device teams looking for an integrated eSuite with strong amendment handling.

How long does it take to build a Phase I study in EDC software?

Build timelines vary significantly across platforms and study complexity. Viedoc's EDC platform delivers study builds typically completed in 2–4 weeks, driven by the no-code Designer that allows certified data managers to configure studies in-house without vendor-managed programming. Enterprise platforms with programmer-dependent study builders typically operate on 60–90 day build cycles. For Phase I, where go-live dates are driven by IND approval and site activation rather than negotiated delivery schedules, build speed is a direct operational constraint — not a secondary consideration.

What compliance certifications should I look for in Phase I EDC software?

At minimum, your Phase I EDC platform should be compliant with FDA 21 CFR Part 11 (electronic records and signatures), ICH GCP E6(R2), and HIPAA for any US-based study handling protected health information (PHI). For EU studies, EU Annex 11 and GDPR compliance are required. ISO 27001 and SOC 2 Type II security certifications provide independent assurance of information security controls, which procurement, IT, and QA stakeholders will routinely request. Availability of a structured CSV package or inspection-readiness documentation reduces your in-house validation burden before first subject in.

What is the Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet is a structured set of audit-ready documentation that Viedoc provides to all customers, designed to support computer system validation requirements and prepare study teams for regulatory inspections. For Phase I teams where QA bandwidth is limited, the VIRP reduces the volume of validation documentation your team needs to produce from scratch, providing a reviewer-ready package that covers the EDC system's validated status, configuration evidence, and operational controls. It's available to all Viedoc customers at no additional cost and is particularly relevant for sponsors and CROs facing their first FDA or EMA inspection on the platform.

What is the difference between per-seat and per-study EDC pricing for Phase I trials?

Per-seat pricing charges for each user with platform access — monitors, investigators, data managers, sponsor reviewers, and QA leads all generate individual license costs. At Phase I, where study teams are lean but access requirements span multiple roles, per-seat models create unpredictable cost as team composition changes. Per-study or study-based pricing charges for the study rather than the user, meaning unlimited seat access is included regardless of how many people need to review data. For Phase I teams managing multiple concurrent studies with variable headcount, study-based pricing with unlimited user seats — the model Viedoc uses — gives consistent cost predictability without licensing friction.

What EDC features matter most for Phase I dose escalation studies?

Dose-escalation studies require fast, reliable amendment handling: when a safety review board clears the next dose level, your eCRF needs to reflect the updated schedule before the next cohort is enrolled. In-house amendment capability — where your data manager can update visit structures, edit checks, and dose fields without waiting on a vendor change queue — is the most operationally critical feature for this design type. Cohort management, multi-dose-level visit structures, and real-time safety data visibility for unblinded reviewers are also relevant. Confirm that your platform supports these in production, not in development, before go-live.

Making the right EDC choice for Phase I clinical trials

The global eClinical software market is estimated at over $11 billion and growing at approximately 14% annually, reflecting the pace at which clinical operations teams are moving away from legacy platforms and consolidating onto modern, cloud-native eClinical suites. Across the platforms in this comparison, the common thread is cloud deployment and a shift away from programmer-dependent configuration — differences emerge in the depth of no-code capability, the maturity of Phase I–specific design templates, and the breadth of the modular suite available without a second vendor relationship.

Platform selection for Phase I should be mapped against three variables: how much in-house configuration capacity your data management team has, how aggressively your protocol is likely to change, and whether you want continuity into Phase II on the same validated platform. Teams with strong in-house CDM capability and a need for rapid amendment turnaround favor platforms that offer genuine no-code independence rather than simplified builders that still require vendor support for complex changes. Organizations prioritizing compliance depth and a full eClinical suite without vendor fragmentation weight module breadth and certification coverage.

The switching costs associated with re-validation and data migration mean a poor Phase I platform choice has consequences that compound. Platform selection at first-in-human is also, effectively, platform selection for Phase II — unless you want to absorb a migration mid-program.

Why Viedoc is the best EDC software for Phase I clinical trials

Viedoc's EDC software delivers the study build speed, in-house configurability, and compliance architecture that Phase I data management teams need from day one. Study builds typically complete in 2–4 weeks. Your CDM team configures studies using Viedoc Designer — a no-code interface designed for data managers, not programmers — which means amendments move at the speed of your protocol decisions, not your vendor's change queue.

The pricing model is transparent and built for Phase I economics: study-based licensing with unlimited user seats, so your sponsor safety monitor, unblinded reviewer, and QA lead can all access the platform without adding per-head license costs. The modular suite — ePRO, RTSM, eTMF, and eSignature — sits on the same validated platform, so your Phase I infrastructure scales into Phase II without a new vendor relationship or a re-validation exercise.

Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, and has run 7,000+ studies across 75+ countries since its founding in Uppsala in 2003. The VIRP gives QA leads a structured, inspection-ready validation package from day one. Support is available 24/7 across global offices, with direct escalation paths that match the urgency of active dosing windows.

If you want to see how Viedoc performs against your Phase I study design and amendment requirements, book a demo or request a proposal.